C12Y 114/16
Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen
Official title: with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
C12Y114/16 (Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen) appears on 88 US grants and 154 published applications in this corpus.
Search patents in C12Y- Granted patents
- 88
- Published applications
- 154
- Assignees
- 88
- Inventors
- 314
- Latest grant
- 7 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 3 | 0 |
| 1998 | 2 | 0 |
| 1999 | 3 | 0 |
| 2000 | 3 | 0 |
| 2001 | 4 | 1 |
| 2002 | 2 | 3 |
| 2003 | 3 | 4 |
| 2004 | 1 | 3 |
| 2005 | 0 | 2 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 1 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 4 |
| 2012 | 0 | 2 |
| 2013 | 1 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 5 |
| 2016 | 6 | 5 |
| 2017 | 2 | 9 |
| 2018 | 2 | 6 |
| 2019 | 9 | 12 |
| 2020 | 7 | 17 |
| 2021 | 5 | 13 |
| 2022 | 5 | 16 |
| 2023 | 3 | 13 |
| 2024 | 10 | 13 |
| 2025 | 8 | 14 |
| 2026 | 4 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Processes for the production of tryptamines7 Apr 2026US 12,595,497 B2Compass Pathfinder Limited
- Gene therapy for treating phenylketonuria10 Mar 2026US 12,569,525 B2The Trustees of the University of Pennsylvania
- PAH-modulating compositions and methods10 Feb 2026US 12,544,458 B2Flagship Pioneering Innovations VI, LLC
- Composition for regulating production of interfering ribonucleic acid13 Jan 2026US 12,522,830 B2Wyvern Pharmaceuticals Inc.
- MRNA therapy for phenylketonuria30 Dec 2025US 12,509,666 B2Translate Bio, Inc.
- Methods for producing modified betalains in yeast3 Sep 2026US 2026/0258343 A1Danmarks Tekniske Universitet
- Gene therapy for treating phenylketonuria6 Aug 2026US 2026/0224650 A1The Trustees of the University of Pennsylvania
- Compositions and methods for integration of viral vectors30 Jul 2026US 2026/0218237 A1Poseida Therapeutics, Inc.
- Optimized PAH gene and expression cassette and use thereof25 Jun 2026US 2026/0174901 A1Suzhou Nggt Biotechnology Co., Ltd.
- Messenger rna with heterologous untranslated regions for enhanced expression and uses thereof25 Jun 2026US 2026/0176597 A1Development Center for Biotechnology
Most cited
By later US patents
- Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system353US 5,082,670 AThe Regents of the University of California · 1992
- AAV-mediated delivery of DNA to cells of the nervous system222US 6,180,613 B2The Rockefeller University · 2001
- Hybrid molecules having translocation region and cell-binding region126US 5,668,255 ASeragen, Inc. · 1997
- In vitro induction of dopaminergic cells88US 5,981,165 ANeurospheres Holdings Ltd. · 1999
- Hybrid molecules having translocation region and cell-binding region85US 6,022,950 ASeragen, Inc. · 2000